Suppr超能文献

一种靶向成纤维细胞活化蛋白-α(FAPα)的三功能诊疗配体。

A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).

作者信息

Kelly James M, Jeitner Thomas M, Ponnala Shashikanth, Williams Clarence, Nikolopoulou Anastasia, DiMagno Stephen G, Babich John W

机构信息

Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, NY, 10065, USA.

Angion Biomedica Corp., Uniondale, NY, 11553, USA.

出版信息

Mol Imaging Biol. 2021 Oct;23(5):686-696. doi: 10.1007/s11307-021-01593-1. Epub 2021 Mar 15.

Abstract

PURPOSE

Fibroblast activation protein-α (FAPα) is uniquely expressed in activated fibroblasts, including cancer-associated fibroblasts that populate tumor stroma and contribute to proliferation and immunosuppression. Radiolabeled FAPα inhibitors enable imaging of multiple human cancers, but time-dependent clearance from tumors currently limits their utility as FAPα-targeted radiotherapeutics. We sought to increase the area under the curve (AUC) by constructing a trifunctional ligand that binds FAPα with high affinity and also binds albumin and theranostic radiometals.

PROCEDURES

RPS-309 comprised a FAPα-targeting moiety, an albumin-binding group, and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Inhibition of recombinant human FAPα (rhFAPα) was determined by colorimetric assay. Affinity for human serum albumin (HSA) was determined by high-performance affinity chromatography. The tissue distribution of [Ga]Ga-RPS-309 in SW872 tumor xenograft-bearing mice was imaged by microPET/CT and quantified by biodistribution studies performed from 30 min to 3 h post injection (p.i.). The biodistribution of [Lu]Lu-RPS-309 was determined at 4, 24, and 96 h p.i.

RESULTS

RPS-309 inhibits rhFAPα with IC = 7.3 ± 1.4 nM. [Ga]Ga-RPS-309 is taken up specifically by FAPα-expressing cells and binds HSA with K = 4.6 ± 0.1 μM. Uptake of the radiolabeled ligand in tumors was evident from 30 min p.i. (> 5 %ID/g) and was significantly reduced by co-injection of RPS-309. Specific skeletal uptake was also observed. Activity in tumors was constant through 4 h p.i., but cleared significantly by 24 h. The AUC in this period was 127 (%ID/g) × h.

CONCLUSIONS

RPS-309 is a high-affinity FAPα inhibitor with prolonged plasma residence. Introduction of the albumin-binding group did not compromise FAPα binding. Although initial tumor uptake was high and FAPα-specific, RPS-309 also progressively cleared from tumors. Nevertheless, RPS-309 incorporates multiple sites in which structural diversity can be introduced, and therefore serves as a platform for future structure-activity relationship studies.

摘要

目的

成纤维细胞活化蛋白-α(FAPα)在活化的成纤维细胞中特异性表达,包括构成肿瘤基质并促进增殖和免疫抑制的癌症相关成纤维细胞。放射性标记的FAPα抑制剂可对多种人类癌症进行成像,但目前肿瘤中随时间的清除限制了它们作为FAPα靶向放射治疗剂的效用。我们试图通过构建一种三功能配体来增加曲线下面积(AUC),该配体以高亲和力结合FAPα,还能结合白蛋白和治疗诊断放射性金属。

程序

RPS-309包含一个FAPα靶向部分、一个白蛋白结合基团和1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)。通过比色法测定重组人FAPα(rhFAPα)的抑制作用。通过高效亲和色谱法测定对人血清白蛋白(HSA)的亲和力。通过微型PET/CT对荷SW872肿瘤异种移植小鼠体内[镓]Ga-RPS-309的组织分布进行成像,并在注射后(p.i.)30分钟至3小时进行生物分布研究进行定量。在注射后4、24和96小时测定[镥]Lu-RPS-309的生物分布。

结果

RPS-309以IC = 7.3±1.4 nM抑制rhFAPα。[镓]Ga-RPS-309被FAPα表达细胞特异性摄取,并以K = 4.6±0.1 μM结合HSA。注射后30分钟(>5%ID/g)肿瘤中放射性标记配体的摄取明显,共注射RPS-309可显著降低摄取。还观察到特异性骨骼摄取。注射后4小时内肿瘤中的活性保持恒定,但在24小时时显著清除。此期间的AUC为127(%ID/g)×小时。

结论

RPS-309是一种具有延长血浆滞留时间的高亲和力FAPα抑制剂。白蛋白结合基团的引入并未损害FAPα结合。尽管最初肿瘤摄取高且具有FAPα特异性,但RPS-309也逐渐从肿瘤中清除。然而,RPS-309包含多个可引入结构多样性的位点,因此可作为未来构效关系研究的平台。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验